ID   M370
AC   CVCL_XJ97
DR   cancercelllines; CVCL_XJ97
DR   Wikidata; Q95984236
RX   PubMed=22194965;
RX   PubMed=24735930;
RX   PubMed=29229836;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965; PubMed=24735930).
CC   Derived from site: Metastatic; Heart; UBERON=UBERON_0000948.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 19-12-24; Version: 8
//
RX   PubMed=22194965; DOI=10.1371/journal.pone.0028973; PMCID=PMC3237573;
RA   Atefi M., von Euw E.M., Attar N., Ng C., Chu C., Guo D.-L., Nazarian R.,
RA   Chmielowski B., Glaspy J.A., Comin-Anduix B., Mischel P.S., Lo R.S.,
RA   Ribas A.;
RT   "Reversing melanoma cross-resistance to BRAF and MEK inhibitors by
RT   co-targeting the AKT/mTOR pathway.";
RL   PLoS ONE 6:e28973.1-e28973.12(2011).
//
RX   PubMed=24735930; DOI=10.1186/1476-4598-13-83; PMCID=PMC4021505;
RA   Lassen A., Atefi M., Robert L., Wong D.J.L., Cerniglia M.,
RA   Comin-Anduix B., Ribas A.;
RT   "Effects of AKT inhibitor therapy in response and resistance to BRAF
RT   inhibition in melanoma.";
RL   Mol. Cancer 13:83.1-83.14(2014).
//
RX   PubMed=29229836; DOI=10.1073/pnas.1712064115; PMCID=PMC5748184;
RA   Su Y.-P., Wei W., Robert L., Xue M., Tsoi J., Garcia-Diaz A.,
RA   Homet Moreno B., Kim J., Ng R.H.-Y., Lee J.W., Koya R.C.,
RA   Comin-Anduix B., Graeber T.G., Ribas A., Heath J.R.;
RT   "Single-cell analysis resolves the cell state transition and signaling
RT   dynamics associated with melanoma drug-induced resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:13679-13684(2017).
//